Search results
Results from the WOW.Com Content Network
Surgical risk, age, perceived life expectancy, and valve durability influence the choice between surgical aortic valve replacement (SAVR) and transcatheter aortic valve implantation. The contemporaneous life expectancy after SAVR, in relation to surgical risk and age, is unknown.
Based on the simulation model, the durability of TAVR valves must be 70% shorter than that of surgical valves to result in reduced life expectancy in older low-risk patients. The threshold for TAVR device durability was substantially higher in younger low-risk patients.
Transcatheter aortic valve replacement (TAVR) becomes the leading therapeutic choice for severe aortic stenosis. There is a growing body of knowledge on long-term survival outcomes, but available data from real-world observational studies are scarce.
From April 2008 to December 2020, a total of 991 patients with symptomatic severe aortic stenosis underwent TAVR with balloon-expandable or self-expanding valves were included. Primary outcomes and survival analysed on base to age <75 years and ≥75 years old.
This data suggests that a 42-year-old patient undergoing aortic valve replacement (AVR) with a tissue valve is expected to live to 58 years of age. In contrast, a 42-year-old in the general population is expected to live to 78 years of age.
Results of the base case examining the impact of the event time ratio (ETR) for transcatheter aortic valve replacement (TAVR) valve durability on life expectancy when patients undergo valve-in-valve TAVR as the initial management strategy for a failed prosthesis.
They found that the loss in life expectancy after SAVR was 0.4 years in patients age 80 years or older. In younger patients however, loss in life expectancy after SAVR was relatively high (4.4 and 3.8 years loss in patients age <50 years and age 50 to 59 years, respectively).
Contemporary data on loss in life expectancy after aortic valve replacement (AVR) are scarce, particularly in younger patients. The purpose of this national, observational cohort study was to analyze long-term relative survival and estimated loss in life expectancy after AVR.
There are scant data on long-term clinical outcomes and bioprosthetic-valve function after transcatheter aortic-valve replacement (TAVR) as compared with surgical aortic-valve...
For AVR plus coronary artery bypass graft procedures, median survival was 10, 8, and 6 years, respectively. Although only 5% of isolated AVR patients had a high Society of Thoracic Surgeons perioperative risk of mortality (≥10%), their median survival was 2.5 to 2.7 years.